| Methods |
three‐mo multicenter parallel trial with third xamoterol arm; endpoints—ET, QOL |
| Participants |
61 pts; *median age 60; 50% male; 94% Class II, 6% Class III; 56% on diuretics; dx—˜67% ischemic
*Note: Figures shown in "Participants" section show composite data from all three study arms, except for number of pts |
| Interventions |
dig dosage 0.25 mg/d |
| Outcomes |
for dig vs pla, no significant difference in ET, QOL |
| Notes |
blind allocation—yes
blinded to outcomes—?
baselines comparable—yes
loss to follow‐up—?
dig titrated to level—no |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Low risk |
A—Adequate |
